In summary, our results show that, at the systemic level, the percentage of the LAP TGF-β1+ subset of CD4+CD25+CD127− Treg cells was increased in advanced-stage lung adenocarcinoma patients. This evidence concerns the gene TGFB1 and lung adenocarcinoma.